Psychedelics Today

Dylan Beynon: At-Home Ketamine Therapy, Big Pharma Pushback, and the Future of Psychedelic Accessibility

In this episode, Joe Moore welcomes Dylan Beynon, CEO and Founder of Mindbloom, one of the largest providers of legal, at-home ketamine therapy in the U.S.

Dylan shares the deeply personal story that led him to psychedelic medicine—including the tragic loss of his mother and sister to addiction and mental illness—and how these experiences continue to fuel his mission to make psychedelic therapy affordable and accessible for all. Mindbloom has now facilitated over 654,000 sessions across 38 states, offering both sublingual and subcutaneous (injectable) ketamine in a comprehensive treatment program that includes preparation, integration, music, journaling, and even generative AI art.

The conversation dives into common criticisms of at-home ketamine, the benefits of guided treatment over IV infusions, and the disturbing influence of Big Pharma in media narratives—especially the growing PR push behind SPRAVATO. Dylan also breaks down what makes Mindbloom's outcomes stand out, why they recently added injectable ketamine, and how their safety data challenges popular misconceptions.

Joe and Dylan also touch on the potential future of at-home MDMA therapy, regulatory hurdles, and what it will take to scale these powerful treatments to millions of people in need.

If you're in the psychedelic field, considering ketamine therapy, or curious about the ethics and economics of psychedelic medicine, this episode offers a powerful look behind the curtain.

Resources:

• Mindbloom.com

• Vital Psychedelic Training

In this episode, we sit down with Victoria Litman, M.Div., J.D., LL.M., to discuss why the future of psychedelic access in the United States is being shaped not by federal agencies, but by the bold actions of individual states. As a legal scholar and writer focusing on drug policy, Victoria breaks down the significance of the FDA's 2024 rejection of psychedelic-assisted therapy, and why that decision might be less of a setback than it seems.

We explore how state-level initiatives like Oregon's Psilocybin Services Act and Colorado's Natural Medicine Health Act are setting the stage for a new model of access—one rooted in harm reduction, personal liberty, and existing regulatory infrastructure. Victoria discusses the importance of the Tenth Amendment and the Anti-Commandeering Doctrine, which allow states to move forward regardless of federal inaction.

Rather than waiting for slow-moving federal institutions, Victoria argues that states can build safe, scalable systems now—especially by leveraging cannabis infrastructure for psychedelic regulation. She also touches on the ethical and cultural implications of this transition, including protections for spiritual and religious use.

If you're wondering what psychedelic policy will look like in the years ahead, this episode offers an insightful and hopeful roadmap.

Link to CATO article

Joe Moore and Anne Philippi are hosts of the PS25 Morning Show! This one features Dee Dee Goldpaugh, LCSW and Tommaso Barba, PhDC!

We talk about all things Sex and Psychedelics!

n this episode of Psychedelics Today, kicking of Psychedelic Science 2025 week in Denver, we sit down with Jonathan Dicksinson, Chief Executive Officer, and Trevor Millar, Chief Operations Officer of Ambio Life Sciences – one of the world's leading ibogaine clinics – to explore the potential of ibogaine for addiction, neuroregeneration, and how ethics, honoring experience, and sustainability will be key to delivering ibogaine at scale.

Trevor shares his early work supporting marginalized populations in Vancouver's Downtown Eastside, which led to the founding of Liberty Root, one of Canada's first ibogaine clinics. Jonathan reflects on his apprenticeship in Mexican clinics, years of international advocacy with the Global Ibogaine Therapy Alliance, and drafting the first set of clinical guidelines for ibogaine detoxification. Together with paramedic and ibogaine safety protocols expert Jose Inzunza, they co-founded Ambio in Tijuana in 2021.

They discuss:

• The unique safety standards Ambio has pioneered – including industry-wide clinical protocols and magnesium therapy to mitigate cardiac risk.

• Their scale: over 3,000 patients treated, with 100+ clients per month across five dedicated houses in Baja California.

• Ambio's groundbreaking neuroregenerative program for Parkinson's, MS, and traumatic brain injury – which has already drawn patients like Brett Favre and Clay Walker.

• How ibogaine appears to drive profound physiological change – including evidence of TBI reversal as shown in Stanford's 2024 study on Special Forces veterans.

• Why ibogaine isn't just a molecule – it opens a long-lasting "critical period" of neuroplasticity that must be supported with preparation, integration, and holistic care.

• The deeper story of sourcing: through his company Terragnosis, Jonathan is the only person with a legal export license for Tabernanthe iboga from Gabon, and Ambio is setting a precedent for reciprocal and ethical global supply chains.

• Their cautionary perspective on Texas' $50M push toward ibogaine clinical trials – and why the traditional "one drug, one indication" model misses the complexity and promise of psychedelic healing.

They also make a compelling case that Ambio is already modeling what the future of psychedelic care should look like – not a single drug in a sterile clinical setting, but a comprehensive, integrated protocol combining preparation, medical oversight, and deep integration. "Start with the end in mind," Trevor urges – Ambio isn't just part of the movement; it's the blueprint for how ibogaine could be delivered worldwide.

Links:

• Ambio Website: https://ambio.life/

• Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis (Frontiers in Immunology, Feb 2025)

• Magnesium–ibogaine therapy in veterans with traumatic brain injuries (Nature Medicine, Jan 2024)

• Ibogaine reduced severe neuropathic pain associated with a case of brachial plexus nerve root avulsion (Frontiers in Pain Research, Aug 2023)

• Novel treatment of opioid use disorder using ibogaine and iboga in two adults (Journal of Psychedelic Studies, Jan 2020)

• Clinical Guidelines for Ibogaine-Assisted Detoxification

• Ambio Life Sciences Launches World's First Clinical Ibogaine Program for Patients With Neurodegenerative Conditions

Bios:

Jonathan Dickinson is the Chief Executive Officer and Co-Founder of Ambio Life Sciences. One of the world's leading experts on ibogaine, Jonathan brings over 15 years of experience in clinical care, traditional practice, and psychedelic research to his leadership at Ambio. A Mexico-licensed psychologist and former Executive Director of the Global Ibogaine Therapy Alliance, he authored the field's foundational safety guidelines and has published widely on ibogaine's therapeutic, cultural, and ecological significance. He holds the only active export license for Tabernanthe iboga root, led the first Nagoya-compliant export from Gabon, and was initiated into the Dissoumba/Fang tradition of Bwiti in 2014 and the Missoko tradition in 2022. He has co-authored peer-reviewed research on ibogaine's potential for trauma, TBI, pain, MS, and Parkinson's. At Ambio, he leads strategy, research, and innovation – advancing a globally scalable model of care that bridges tradition, science, and integrity.

Trevor Millar is the Chief Operating Officer and Co-Founder of Ambio Life Sciences. A social entrepreneur and pioneer in ibogaine advocacy and treatment, Trevor brings over a decade of experience supporting individuals through addiction recovery, trauma healing, and post-treatment integration. His background includes co-founding the Canadian Psychedelic Association and serving as Chair of the Board for MAPS Canada. He has co-authored peer-reviewed research on ibogaine's applications for trauma, TBI, and opioid use disorder, and has been featured in award-winning documentaries including DOSED and In Waves and War. Grounded in personal experience and guided by a philosophical approach to healing, Trevor is helping shape a new model for ethical, integrative psychedelic care on a global scale. At Ambio, Trevor leads operations, strategic partnerships, and client experience – bridging clinical care with systems design, education, and public advocacy.

In this episode of Psychedelics Today, hosts sit down with Jeff Breau from Harvard Divinity School's Center for the Study of World Religions. Key themes include the intersection of psychedelics and religion, harm reduction practices, and the burgeoning psychedelic church movement. Jeff brings insights from his ethnographic research on psychedelic churches and discusses the importance of interdisciplinary collaboration for advancing understanding in this field. He also delves into the role of music in psychedelic therapy, critiques of the Mystical Experience Questionnaire (MEQ), and the potential for psychedelic chaplaincy. Tune in for an enlightening conversation on the evolving landscape of psychedelics in society and spirituality.

00:00 Introduction and Welcome

00:18 Music in Psychedelic Therapy

02:13 Cultural Context of Music in Therapy

06:08 Personal Journey into Psychedelics and Religion

08:40 Living at an Ashram and Spiritual Practices

15:52 Mystical Experience Questionnaire (MEQ)

33:01 Psychedelic Churches and Legal Challenges

46:11 The Intersection of Law and Religion

46:34 Emergence of Psychedelic Churches

48:41 The Democratization of Mystical Experiences

49:49 Technologies of Revelation

51:10 Novel Rituals and Spiritual Practices

53:49 Humor and Irreverence in Religion

56:44 Reevaluating the Term 'Cult'

01:10:11 Psychedelic Chaplaincy and Spiritual Care

01:18:44 Burning Man as a Model for Religiosity

01:22:43 The Rise of Iboga in American Christianity

01:25:56 Conclusion and Future Directions

https://cswr.hds.harvard.edu/people/jeffrey-breau

In this episode, Joe Moore sits down with Paul Gillis-Smith from The Center for the Study of World Religions to discuss a range of fascinating topics. They begin by discussing the Harvard Divinity School and the CSWR's mission and history. The conversation delves into the work and legacy of Lisa Bieberman, a pivotal figure in the 1960s psychedelic harm reduction movement. It explores her contributions to the field through her Psychedelic Information Center. They also touch on the Quaker traditions and their intersection with LSD use, showing how spirituality and psychedelics can coalesce. Paul also talks about upcoming psychedelic and chaplaincy workshops, emphasizing the importance of spiritual care in psychedelic experiences. This episode is rich with historical insights and contemporary applications, making it a must-listen for anyone interested in psychedelics and spirituality.

Paul Gillis-Smith @ CSWR

Center for the Study of World Religions

Psychometric brahman, psychedelic science: Walter Stace, transnational Vedanta, and the Mystical Experience Questionnaire

00:00 Introduction and Initial Setup

00:34 Meeting at Penn's Psychedelic Conference

01:14 Postdoctoral Presentations and Indigenous Plant Medicine

03:27 Understanding CSWR and Its Evolution

07:21 Harvard's Study of Psychedelics in Society and Culture

09:11 Personal Academic Journey and Interest in Psychedelics

11:58 Role at CSWR and Ongoing Projects

18:59 Lisa Bieberman: A Pioneer in Psychedelic Education

40:53 Quaker Theology of LSD

41:58 Meeting Structure and Frequency

42:46 Profound Simple Truths

45:41 Transition to Quakerism

48:45 The New Jerusalem Prophecy

53:02 Quakerism and Its Influence

01:11:25 Clinical Chaplaincy and Psychedelics

01:18:39 Conclusion and Future Projects

In this episode of Psychedelics Today, Joe Moore speaks with Dr. Simon Ruffell, a London-based psychiatrist, researcher, and curandero-in-training in the López Mahua lineage of the Shipibo tradition. Dr. Ruffell shares how his early fascination with psychiatry eventually led to a deep disillusionment with the limitations of conventional treatments—and a surprising pivot toward the Amazon.

Now working at the intersection of Indigenous healing and clinical research, Ruffell describes his journey from medical school to shamanic apprenticeship. He offers insight into the Shipibo understanding of illness across three planes—spiritual, psychological, and physical—and how these ideas challenge Western frameworks.

The conversation explores critical questions about the psychedelic renaissance: Are current clinical models missing the energetic and spiritual dimensions of healing? What are the risks of poorly held psychedelic sessions, and how can Indigenous knowledge guide safer practices? Dr. Ruffell advocates for deep training, cross-cultural respect, and collaborative models—such as pairing Indigenous healers with psychiatrists in clinical settings.

He also discusses his work with Onaya Science and Onaya.io, organizations that partner with Indigenous communities to study the effects of ayahuasca, particularly in treating PTSD among military veterans. Early findings from their five-year study show that 84% of participants no longer meet PTSD criteria six months after retreat—a promising signal for integrative approaches.

This episode offers a rare look at how science and spirituality can coexist. Whether you're a clinician, researcher, or someone seeking deeper healing, Dr. Ruffell's story invites us to question our assumptions and expand our understanding of what true medicine can be.

Aspen Psychedelic Symposium 2024 – Hosted by Kevin Franciotti

This powerful panel explores the healing potential and complex responsibilities that come with working with Ibogaine, a potent plant-based psychedelic. Moderator Kevin Franciotti guides a heartfelt and informative conversation with Talia Eisenberg, Tom Feegel, and Dr. Lola "Dr. O" Hoba, highlighting personal transformation, medical protocols, and the importance of honoring traditional knowledge.

Talia Eisenberg shares her recovery from opioid addiction and the founding of BEOND Ibogaine, a medical treatment center in Cancun, Mexico. Her story illustrates the plant's unique power to interrupt addiction and awaken purpose. Tom Feegel, co-founder and CEO of BEOND, shares how his own trauma and long-term sobriety inspired a vision for a safe, respectful, and medically supervised environment for deep healing.

Dr. Lola Hoba offers insights as a pharmacist and Yoruba herbalist, bridging traditional plant medicine knowledge with modern pharmacology. She describes how iboga works on multiple brain receptors and why it holds so much promise for treating addiction, depression, and trauma. She also cautions about its cardiac risks and calls for respectful, trained facilitation.

Panelists discuss the rigorous safety protocols at BEOND, including ICU-level care, psychiatric screening, and pre-treatment evaluations. They also explore broader questions: How can this medicine be offered responsibly? What does reciprocity mean in practice? BEOND supports Blessings of the Forest, a nonprofit in Gabon that works to stop poaching and protect Indigenous access to the sacred root.

This conversation highlights the importance of blending science, spirit, and social justice. From trauma healing to sustainable sourcing, each panelist emphasizes the need for compassion, caution, and connection. As laws change and access grows, the panel urges all involved to move forward with care—for the medicine, the people it serves, and the cultures that have stewarded it for generations.